


**Figure 1: Structure of the 13-CRA parent-metabolite model**

### *Visual Predictive Check*

The VPC of the final model was stratified according to the formulations for 13-CRA and according to day for 4-oxo-13-CRA (Figure 2). The VPC plots show that the model is able to explain both the central tendency and variability in the PK observations for 13-CRA, for both the new liquid and reference capsule-extracted 13-CRA. The VPC also demonstrate that the model is able to adequately explain the 4-oxo-13-CRA data on day 1, however there is a slight overestimation of the 95th percentile of 4-oxo-13-CRA data. The extent of the overestimation is small and is not considered to invalidate the model. Nevertheless, caution should be used when simulating steady-state profiles for 4-oxo-13-CRA.



**Figure 2 : VPC plots for liquid and capsule: 13-CRA (upper panel) and 4-oxo-13-CRA (lower panel).** The VPC plot shows grey and black horizontal lines depicting the 5<sup>th</sup>, 50<sup>th</sup> and 95<sup>th</sup> percentiles of the prediction-corrected observed data in each bin, along with shaded regions depicting the limits of the 90% confidence intervals around the 5<sup>th</sup>, 50<sup>th</sup> and 95<sup>th</sup> percentiles of the prediction-corrected simulated data.

**Table 1: Model Parameters**

Parameter	Unit	Estimate	RSE [%]	LLCI	ULCI	Description
<i>Fixed effects (THETA)</i>						
$k_{tr}$	$h^{-1}$	9.23	27.002	4.345	14.115	Transit compartment rate constant for typical patient administered liquid formulation
KA	$h^{-1}$	0.249	63.606	-0.061	0.559	Absorption rate constant for typical patient
$^1CL_P^{pop}$	L/h	9.74	30.294	3.957	15.523	Clearance of 13-CRA for a typical patient
$^1V_P^{pop}$	L	41.15	--	--	--	Volume of distribution of 13-CRA for a typical patient
$^1CL_M^{pop}$	L/h	2.66	56.809	-0.302	5.622	Clearance of 4-OIT for a typical patient
$^1V_M^{pop}$	L	30.3	29.658	12.686	47.914	Volume of distribution of 4-OIT for a typical patient
F1		1.65	4.204	1.514	1.786	Relative bioavailability of liquid formulation with respect to the extracted capsule
$k_{45}$	$h^{-1}$	0.1047	--	--	--	Rate constant governing simplified enterohepatic recycling model
$k_{54}$	$h^{-1}$	0.05652	--	--	--	Rate constant governing simplified enterohepatic recycling model
<i>Random effects: Inter-individual variability (OMEGA) diagonal elements</i>						
$V_P (\omega^2)$	-	1.6	166.23 1	-3.613	6.813	Inter-individual variability on $V_P$
$V_P (CV)^2$	%	198.82				
$V_P (Sh)^3$	%	4.87				
$CL_P (\omega^2)$	-	0.141	110.27 9	-0.164	0.446	Inter-individual variability on $CL_P$
$CL_P (CV)^2$	%	38.91				
$CL_P (Sh)^3$	%	5.25				
$CL_M (\omega^2)$	-	0.392	106.41 5	-0.426	1.21	Inter-individual variability on $CL_M$
$CL_M (CV)^2$	%	69.28				
$CL_M (Sh)^3$	%	5.16				
<i>Random effects: Inter-individual variability (OMEGA) off-diagonal elements</i>						
$V_P$ and $CL_P (\omega^2)$	-	0.346	175.24 2	-0.842	1.534	
$V_P$ and $CL_M (\omega^2)$	-	0.517	189.90 8	-1.407	2.441	
$CL_P$ and $CL_M (\omega^2)$	-	0.23	103.90 1	-0.238	0.698	
<i>Residual error (SIGMA)</i>						
$Err_{parent} (\sigma^2)$	-	0.39	17.521	0.256	0.524	Variance of exponential residual error for 13-CRA.
$Err_{parent} (CV)^4$	%	69.06		54.01	82.99	
$Err_{parent} (\sigma^2)$	-	46656	19.44	17875.42 26	88983.48 66	Variance of additive <sup>5</sup> residual error for 13-CRA.
$Err_{parent} (CV)^5$	%	21.6		13.37	29.83	
$Err_{metabolite}$ at Day=1 ( $\sigma^2$ )	-	0.793	14.386	0.569	1.017	Variance of exponential residual error for 4-OIT on day 1
$Err_{metabolite}$ at Day=1 ( $CV$ ) <sup>4</sup>	%	110		87.55	132.85	
$Err_{metabolite}$ at Day=14 ( $\sigma^2$ )	-	0.139	21.206	0.081	0.197	Variance of exponential residual error for 4-OIT on day $\geq 14$

Err <sub>metabolite at Day=14</sub> (CV) <sup>4</sup>	%	38.62		29.05	46.66	
<p>LLCI = lower limit of 95% confidence interval (estimate – 1.96·SE)          ULCI = upper limit of 95% confidence interval (estimate + 1.96·SE)          RSE = relative standard error (100·SE/estimate)  <sup>1</sup> Apparent PK parameter, equivalent to CL<sub>pop</sub>/F and V/F, where F is the absolute bioavailability of the capsule formulation.  <sup>2</sup> The coefficient of variation (CV) is calculated as 100·SQRT(EXP(OMEGA<sup>2</sup>)-1)  <sup>3</sup> Shrinkage (Sh) calculated as 100·(1-standard deviation of individual eta estimates/ω)  <sup>4</sup> The coefficient of variation (CV) is calculated as 100·SQRT(EXP(OMEGA<sup>2</sup>)-1)  <sup>5</sup> The coefficient of variation (CV) is calculated as 100·SQRT(SIGMA<sup>2</sup>)/1000, which is the CV for an observation of 1000 ng/mL.  <sup>6</sup> This parameterization of the residual error model approximates an additive structure on the untransformed scale.</p>						

k<sub>tr</sub>, transit compartment rate constant, KA, absorption rate constant; V<sub>p</sub> and V<sub>M</sub> volume of distribution for the central compartments of the parent (13-CRA) and the metabolite (4-OIT), respectively; k<sub>45</sub> and k<sub>54</sub>, are the rate constants between central and peripheral compartments for the parent; k<sub>46</sub> and k<sub>60</sub>, are the elimination rate constants for the parent and the metabolite; CL<sub>P</sub> and CL<sub>M</sub>, respectively are the clearance for the parent and the metabolite while CL<sub>P</sub><sup>pop</sup>, CL<sub>M</sub><sup>pop</sup>, V<sub>P</sub><sup>pop</sup> and V<sub>M</sub><sup>pop</sup>, respectively are the estimated clearance and volume of distribution for a typical patient.